Episode 9: Nina Bauer, MilliporeSigma & Lance Holland, bluebird bio – Part 2

Diana
11 December 2020
SHARE NOW

NINA AND LANCE JOIN US AGAIN TO CONTINUE OUR DISCUSSION AND SHARE PREDICTIONS ON MESOBLAST’S FDA RULING

Part 2 of Anthony and Michael’s meet up to Nina Bauer and Lance Holland.

The bulk of the chat was around Mesoblast’s pending FDA decision for Ryoncil, their pediatric graft versus host disease therapy.

The panel took it to a vote on will it be approved or rejected. Listen and find out how the panel judged it. and of course you can see the widely reported outcome in various news outlets.

DISCLAIMER: opinions expressed are solely the interviewee’s own and do not express the views or opinions of their respective employers

Register for FREE for Phacilitate’s next member event! Advanced Therapies Connect will take place on the 26-27 January 2021 and will be 100% virtual!

https://www.advancedtherapiesconnect.com/

Lance’s link to Mass Bio Ed  https://www.massbioed.org 

Dark Horse are recruiting! https://darkhorseconsultinggroup.com/careers

And so is Nina’s team at MilliporeSigma! https://www.merckgroup.com/en/careers.html

Finally, if you’re not already, don’t forget to sign-up as a Phacilitate member, it’s FREE! Every fortnight you’ll get the latest market intelligence, new ideas and exclusive event offers straight to your inbox.

Join a community with the same goal; to help advance a new standard in healthcare. https://www.phacilitate.co.uk/membership 

Enjoy and, as always, please share your feedback.

Finally, if you’re not already, don’t forget to sign-up as a Phacilitate member, it’s FREE! Every fortnight you’ll get the latest market intelligence, new ideas and exclusive event offers straight to your inbox.

Join the Phacilitate community and enjoy 100s of insight packed articles and videos

Already a member?
Sign In